Levodopa deuterated - Auspex Pharmaceuticals

Drug Profile

Levodopa deuterated - Auspex Pharmaceuticals

Alternative Names: Deuterium containing levodopa - Auspex Pharmaceuticals; Deuterium substituted levodopa - Auspex Pharmaceuticals; SD-1077

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator Imphar AG
  • Developer Auspex Pharmaceuticals
  • Class Antiparkinsonians; Catecholamines; Organic deuterium compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 16 Mar 2015 Auspex Pharmaceuticals has patent protection for levodopa deuterated in USA and European Union (Auspex Pharmaceuticals 10-K, March 2015)
  • 12 Jan 2015 Preclinical trials in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top